Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780609 | 0.88 | MAOA (0.44) | LMNAPKMHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL14273445 | 0.84 | ALDH1A1 (0.52) | LMNAPKMRAB9AHPGDALDH1A1 | |
| SCHEMBL4582989 | 0.72 | L3MBTL1 (0.53) | LMNAPKMALDH1A1SMN1; SMN2 | |
| SCHEMBL4981378 | 0.69 | MEN1 (0.52) | ALDH1A1 | |
| SCHEMBL4980300 | 0.68 | MEN1 (0.50) | — | |
| Darenzepine SCHEMBL996265 | 0.67 | MEN1 (0.52) | LMNAPKMRAB9AHPGDALDH1A1 | |
| SCHEMBL5620994 | 0.66 | FAAH (0.39) | RAB9AHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL9431127 | 0.66 | PTGS2 (0.52) | RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL4726272 | 0.65 | NFE2L2 (0.48) | LMNAALDH1A1 | |
| SCHEMBL4981734 | 0.64 | CDC25A (0.47) | LMNARAB9AHPGDALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1897864-A1 | Anthracene derivatives and the use thereof for treating benign and malignant tumors | AEterna Zentaris GmbH (DE) | 2008-03-12 | — | — | EP | claimed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | claimed |
| EP-1897864-A1 | Anthracene derivatives and the use thereof for treating benign and malignant tumors | AEterna Zentaris GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1897864-A1 | Anthracene derivatives and the use thereof for treating benign and malignant tumors | AEterna Zentaris GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008015265-A1 | ANTHRACEN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOROUS DISEASES | ÆTERNA ZENTARIS GMBH (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | TUBB1, TUBA1C, TUBB3 | LMNA 225/4885PKM 1308/4885RAB9A 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.